公开(公告)号：EP3792257B1

公开(公告)日：2024-07-17

申请号：EP19798903.1

申请日：2019-05-06

IPC分类号： C07D403/12 ,  A61K31/506 ,  A61P35/00

CPC分类号： A61P35/00 ,  C07D403/12

公开(公告)号：EP3388420B1

公开(公告)日：2022-06-22

申请号：EP16872373.2

申请日：2016-12-06

发明人： FAN, Lei ,  DU, Wu ,  LI, Xinghai ,  CHEN, Yuanwei ,  XU, Kexin ,  CHEN, Ke ,  ZHANG, Shaohua ,  LUO, Tongchuan

IPC分类号： C07D215/36 ,  C07D401/04 ,  C07D401/12 ,  A61K31/47 ,  A61K31/4709 ,  A61P19/06 ,  A61P19/02 ,  A61P9/12 ,  A61P9/00 ,  A61P13/12 ,  A61P39/02 ,  A61P17/06

公开(公告)号：EP4403167A1

公开(公告)日：2024-07-24

申请号：EP21957132.0

申请日：2021-09-17

申请人： Hinova Pharmaceuticals Inc.

发明人： WEI, Xing ,  KUANG, Tongtao ,  CHEN, Jiang ,  AI, Chaowu ,  LI, Xinghai

IPC分类号： A61K9/22 ,  C07D215/36 ,  C07D215/06 ,  C07D215/42 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4375 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P19/06

CPC分类号： A61K9/20 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/4375 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P19/06 ,  C07D215/06 ,  C07D215/36 ,  C07D215/42

摘要： Disclosed in the present invention is a quinoline compound sustained-release tablet, which contains the following raw and auxiliary materials in parts by weight: 1-40 parts of a quinoline compound, 100-300 parts of a filler, 50-200 parts of a sustained-release material and 0.5-4 parts of a lubricant. The filler comprises, but is not limited to, mannitol, microcrystalline cellulose, lactose, starch, corn starch, calcium hydrogen phosphate hydrate, magnesium carbonate, calcium carbonate, purified sucrose and/or glucose; the sustained-release material comprises, but is not limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and povidone, glyceryl behenate, and/or a long-chain fatty acid; and the lubricant comprises, but is not limited to, magnesium stearate, calcium stearate, sucrose fatty acid ester, sodium stearyl fumarate, polyethylene glycol, talc, glyceryl behenate and/or stearic acid.

公开(公告)号：EP4378936A1

公开(公告)日：2024-06-05

申请号：EP22848701.3

申请日：2022-07-29

申请人： Hinova Pharmaceuticals Inc.

发明人： DU, Wu ,  LI, Xinhai ,  WEN, Kun ,  QIN, Dekun ,  ZHANG, Shaohua ,  CHEN, Song ,  DUAN, Jingyi ,  LV, Haibin ,  LI, Haibo ,  LI, Yu ,  HE, Jinyun ,  CHEN, Muyang ,  LIU, Shijuan ,  FU, Yiwei ,  GUAN, Yikai ,  TU, Zhilin

IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K31/496 ,  A61K31/4439 ,  A61P35/00

CPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/519 ,  A61P11/00 ,  A61P17/10 ,  A61P17/14 ,  A61P31/14 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/10 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D498/04 ,  C07D519/00 ,  C07D401/04 ,  A61K31/4439

摘要： A compound as shown in formula I, or an optical isomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a tautomer thereof, a mesomer thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture form thereof, a metabolite thereof, a metabolic precursor thereof, or an isotope substitute form thereof. TB is a target recognition/binding portion, L is a linking portion, and U is a ubiquitin protease recognition/binding portion, the three portions being connected by means of chemical bonds. The compound can significantly down-regulate mutated androgen receptor (AR) proteins, and has good inhibitory activity on prostate cancer cell lines. The compound of formula I can be used for preparation of a protein degradation targeted chimera for targeted regulation of androgen receptors, and a drug for treating diseases correlated with regulation by androgen receptors, and has particularly good application prospects in drugs for treating prostate cancers and breast cancers.

公开(公告)号：EP3388420A1

公开(公告)日：2018-10-17

申请号：EP16872373.2

申请日：2016-12-06

申请人： Hinova Pharmaceuticals Inc.

发明人： FAN, Lei ,  DU, Wu ,  LI, Xinghai ,  CHEN, Yuanwei ,  XU, Kexin ,  CHEN, Ke ,  ZHANG, Shaohua ,  LUO, Tongchuan

IPC分类号： C07D215/36 ,  C07D401/04 ,  C07D401/12 ,  A61K31/47 ,  A61K31/4709 ,  A61P19/06 ,  A61P19/02 ,  A61P9/12 ,  A61P9/00 ,  A61P13/12 ,  A61P39/02 ,  A61P17/06

CPC分类号： C07D215/36 ,  A61K31/47 ,  A61K31/4709 ,  C07D401/04 ,  C07D401/12

摘要： The present invention discloses quinoline compounds, a preparation method thereof and a use thereof as a urate transporter inhibitor drug. The compounds and salts, hydrates or solvates provided in the present invention, as a selective uric acid reabsorption inhibitor, can be used in the treatment of hyperuricemia and gout by promoting uric acid to excrete from the body and reducing serum uric acid, and have the effect of reducing the uric acid in the animal body and human body.

公开(公告)号：EP4368614A1

公开(公告)日：2024-05-15

申请号：EP22836982.3

申请日：2022-07-06

申请人： Hinova Pharmaceuticals Inc.

发明人： FAN, Lei ,  YU, Hua ,  WANG, Fei ,  AI, Chaowu ,  XU, Kexin ,  LIU, Xingtai ,  DU, Jing ,  PENG, Ying ,  LUO, Tongchuan ,  PENG, Shiming ,  TAN, Bin ,  XIAO, Daibiao ,  HUO, Yongxu ,  LIU, Chengcheng ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D239/48 ,  C07D241/26 ,  C07D249/14 ,  A61P35/00

CPC分类号： A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/55 ,  A61K38/05 ,  A61P35/00 ,  A61P35/02 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D519/00 ,  C07K5/06017 ,  C07D249/14 ,  C07D239/48 ,  C07D241/26

摘要： A synthesis and an application of a phosphatase degrader, belonging to the field of chemical medicine. The phosphatase degrader is a compound represented by formula I, or a salt thereof, or a deuterated compound thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof. The compound can be used as a phosphatase degrader, especially as an SHP2 protein degrader, can treat malignant diseases such as tumors, and has good application prospects.

公开(公告)号：EP3020714A4

公开(公告)日：2016-10-26

申请号：EP14805136

申请日：2014-05-27

申请人： HINOVA PHARMACEUTICALS INC

发明人： CHEN YUANWEI ,  GONG YU

IPC分类号： C07D401/04 ,  A61K31/4439 ,  A61P5/28 ,  A61P13/08 ,  A61P17/10 ,  A61P17/14 ,  A61P35/00

CPC分类号： C07D401/04

公开(公告)号：EP3020714A1

公开(公告)日：2016-05-18

申请号：EP14805136.0

申请日：2014-05-27

申请人： Hinova Pharmaceuticals Inc.

发明人： CHEN, Yuanwei ,  GONG, Yu

IPC分类号： C07D401/04 ,  A61K31/4439 ,  A61P5/28 ,  A61P17/14 ,  A61P17/10 ,  A61P35/00 ,  A61P13/08

CPC分类号： C07D401/04

摘要： Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds possess androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.

摘要翻译： 提供了式（I）的咪唑烷二酮化合物，其制备方法，用途和药物组合物。 所述咪唑烷二酮化合物具有雄激素受体拮抗剂活性并可用于预防和治疗与雄激素受体有关的疾病和病症，例如前列腺癌，脱发，毛发再生，痤疮和青春期痤疮。

公开(公告)号：EP3730484B1

公开(公告)日：2024-02-28

申请号：EP18890728.1

申请日：2018-12-20

发明人： DU, Wu ,  AI, Chaowu ,  LI, Yu ,  WEN, Kun ,  LV, Haibin ,  REN, Wen ,  HE, Jinyun ,  QIN, Dekun ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D413/12 ,  A61K31/4245 ,  A61P27/12 ,  A61P25/00 ,  A61P37/02 ,  A61P35/00

公开(公告)号：EP3683214A1

公开(公告)日：2020-07-22

申请号：EP18855304.4

申请日：2018-09-14

申请人： Hinova Pharmaceuticals Inc.

发明人： FAN, Lei ,  XU, Kexin ,  CHEN, Ke ,  WANG, Fei ,  WU, Xiaoquan ,  LUO, Tongchuan ,  ZHANG, Shaohua ,  LI, Xinghai ,  CHEN, Yuanwei

IPC分类号： C07D401/14 ,  C07D239/91 ,  A61K31/517 ,  A61K31/553 ,  A61K31/555 ,  A61P35/00 ,  A61P29/00

摘要： Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug.